Compare TransMedics Group Inc (TMDX) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Vistra Corp — how do they compare? TransMedics Group Inc trades at $87.02 (market cap $3.10B), while Vistra Corp trades at $146.99 (market cap $48.64B). The key difference: Vistra Corp is far larger — about 15.7× TransMedics Group Inc's market cap, and Vistra Corp pays a 0.63% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | VST | |
|---|---|---|
Market Cap | $3.10B | $48.64B |
Sector | Technology | Technology |
52-Week High | $150.42 | $217.92 |
52-Week Low | $61.99 | $134.71 |
Enterprise Value | $3.49B | $70.58B |
Dividend Yield | — | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Vistra (VST) trades at $146.68, up 2.67% today, with a bearish technical signal from moving averages but strong analyst support (90.9% buy ratings). Recent Q2 2026 earnings showed a beat on EPS ($2.87 actual vs. $1.32 expected) but a revenue miss, while the company reaffirmed full-year guidance amid growing data center power demand. The stock's valuation includes a P/E of 24.44 and a high ROE of 75.73%, though net cash flow was negative in 2025.
The outlook is positive due to robust EBITDA growth and strategic positioning in the AI power sector, with a consensus price target of $239.75 implying significant upside. Key risks include ERCOT market volatility, hedging losses, and high debt levels, requiring monitoring of execution on data center deals and cost controls.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
